about
Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials.Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-α2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trial.Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial.
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mitchell N Davis
@ast
Mitchell N Davis
@en
Mitchell N Davis
@es
Mitchell N Davis
@nl
type
label
Mitchell N Davis
@ast
Mitchell N Davis
@en
Mitchell N Davis
@es
Mitchell N Davis
@nl
prefLabel
Mitchell N Davis
@ast
Mitchell N Davis
@en
Mitchell N Davis
@es
Mitchell N Davis
@nl
P106
P31
P496
0000-0002-0526-5564